Jeryl Hilleman became a director of Novocure in July 2018. Ms. Hilleman is Chief Financial Officer of Intersect ENT, a medical device company with commercial products for the treatment of chronic sinusitis. Prior to joining Intersect ENT, she was Chief Financial Officer of Amyris Inc., a multi-national, renewable products company based in California and Brazil, from 2008 to 2012. Ms. Hilleman was a member of the board of directors and chair of the audit committee at Xenoport Inc., from 2004 to July 2018. She also served as Chief Financial Officer of Symyx Technologies, Ocera and Cytel. She is also a director of Minerva Neurosciences. Ms. Hilleman holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.